SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs soars on receiving approvals from USFDA

11 Mar 2019 Evaluate

Laurus Labs is currently trading at Rs. 366.00, up by 15.90 points or 4.54% from its previous closing of Rs. 350.10 on the BSE.

The scrip opened at Rs. 360.00 and has touched a high and low of Rs. 371.40 and Rs. 354.50 respectively. So far 716085 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 542.95 on 13-Mar-2018 and a 52 week low of Rs. 324.00 on 18-Feb-2019.

Last one week high and low of the scrip stood at Rs. 371.40 and Rs. 340.45 respectively. The current market cap of the company is Rs. 3842.37 crore.

The promoters holding in the company stood at 33.50%, while Institutions and Non-Institutions held 46.38% and 20.13% respectively.

Laurus Labs has received a final approval from the United States Food and Drug Administration (USFDA) for Hydroxychloroquine Tablets 200 mg.

In another development, the Company also received a tentative approval for an ANDA for ADL (Abacavir, Dolutegravir, and Lamivudine) Tablets 600 mg/50 mg/300 mg from USFDA.

The products will be commercialized from Laurus' manufacturing site located at Atchutapuram, Visakhapatnam.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1135.00 5.40 (0.48%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×